AGX51
Based on 10 publication(s) in Google Scholar
AGX51 is the first-in-class pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist and degrader. AGX51 inhibits Id1-E47 interaction, leading to ubiquitin-mediated degradation of Ids, cell growth arrest, and viability reduction. AGX51 can inhibit TNBC and has an IC50 of about 25 nM. AGX51 can be used in cancer research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.33%
- CAS No.: 330834-54-3
- Formule: C27H29NO4
- Masse moléculaire:431.52
-
Stockage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) AGX51
More- Cell Mol Immunol. 2025 Mar;22(3):300-315. [Abstract]
- J Exp Clin Cancer Res. 2024 Aug 10;43(1):222. [Abstract]
- Glia. 2024 Jul;72(7):1236-1258. [Abstract]
- Front Cell Dev Biol. 2021 Feb 12:9:616610. [Abstract]
- Cancers (Basel). 2026 Apr 8;18(8):1186. [Abstract]
- Mol Oncol. 2025 Mar 21. [Abstract]
- San Diego State University
- Norwegian University of Science and Technology. 2024 May.
- bioRxiv. 2023 Oct 4.
- Leiden University. 9 (2021): 182.
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
IC50: 26.66 μM (4T1), 8.7 μM (HMLE RAS Twist), 22.28 μM (MDA-MB-157), 30.91 μM (MDA-MB-436), 36.55 μM (SK-BR-3), 60 μM (MCF-7), 10.89 μM (PDX-BR7), 11.97 μM (PDX-IBT) , 18.56 μM (PDX-BR11)[1]
AGX51 (0-80 μM; 24 h) decreases ID1 protein levels in 4T1 cells[1]. AGX51 (40 μM; 0-72 h) decreases ID1 levels protein with a 40 μM concentratio in 4T1 cells[1]. AGX51 (40 μM; 24 h) influences 4T1 cells , ER+, HER2+, TNBC and three breast cancer PDX cell ines[1]. AGX51 (0-80 μM; 24-48 h) influences cell cycle of 4T1 cells[1]. AGX51 (40 μM; 4-24 h) influences phospho-histone H3 levels in 4T1 cells[1]. AGX51 (40 μM; 24 h) influences ROS levels in 4T1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:4T1 cells
-
Concentration:0, 5, 10, 20, 40 and 80 μM
-
Incubation Time:24 hours
-
Result:Decreased ID1 protein levels starting at a concentration of 40 μM in 4T1 cells.
-
Cell Line:4T1 cells
-
Concentration:40 μM
-
Incubation Time:0, 2, 4, 8 , 12, 24, 48 and 72 hours
-
Result:Decreased ID1 protein levels starting at 4 h, while until 24 h ID1 protein completely loss.
-
Cell Line:4T1 cells, HMLE RAS Twist, MDA-MB-157, MDA-MB-436, MDA-MB-231, MDA-MB-453, BT-474, MDA-MB-361, SK-BR-3, MCF-7, T47-D, PDX-BR7, PDX-IBT and PDX-BR11
-
Concentration:40 μM
-
Incubation Time:24 hours
-
Result:Inhibited 4T1, HMLE RAS Twist, MDA-MB-157, MDA-MB-436, SK-BR-3, MCF-7, PDX-BR7, PDX-IBT and PDX-BR11 cell lines with IC50s of 26.66, 8.7, 22.28, 30.91, 36.55, 60, 10.89, 11.97 and 18.56 μM, respectively.
-
Cell Line:4T1 cells
-
Concentration:40 μM
-
Incubation Time:24 and 48 hours
-
Result:Affected cell cycle of 4T1 cells with a G0/G1 phase accumulation.
-
Cell Line:4T1 cells
-
Concentration:40 μM
-
Incubation Time:4 and 24 hours
-
Result:Reduced phospho-histone H3 levels in 4T1 cells.
-
Cell Line:4T1 cells
-
Concentration:40 μM
-
Incubation Time:24 hours
-
Result:Increased ROS level of 4T1 cells and indicated ROS production is a main mechanism of cell killing.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c mice with luciferase-labeled 4T1 cells[1]
-
Dosage:50 mg/kg
-
Administration:Intraperitoneal injection; 60 mg/kg twice a day; for 4 weeks
-
Result:Inhibited lung metastasis development.
-
Animal Model:A/J mice with AOM colon tumor model[1]
-
Dosage:15 mg/kg
-
Administration:Intraperitoneal injection; 15 mg/kg twice a day; for 3 weeks
-
Result:Dreased the colon tumors and exhibited anti-tumor activity in AOM colon tumor mice.
Chemical Information
-
CAS No. 330834-54-3
-
Appearance Oil
-
Masse moléculaire 431.52
-
Formule C27H29NO4
-
Color Light yellow to yellow
-
SMILES
CCC(N(CCC(C1=CC=C(OCO2)C2=C1)C3=CC=CC=C3OC)CC4=CC=CC=C4)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Cell Mol Immunol
The AhR-Ovol1-Id1 regulatory axis in keratinocytes promotes epidermal and immune homeostasis in atopic dermatitis-like skin inflammation. [Abstract]2025 Mar;22(3):300-315. PMID: 39939818 -
J Exp Clin Cancer Res
Autophagy-mediated ID1 turnover dictates chemo-resistant fate in ovarian cancer stem cells. [Abstract]2024 Aug 10;43(1):222. PMID: 39123206 -
Glia
ID factors regulate the ability of Müller glia to become proliferating neurogenic progenitor-like cells. [Abstract]2024 Jul;72(7):1236-1258. PMID: 38515287 -
Front Cell Dev Biol
TGF-β-Induced Endothelial to Mesenchymal Transition Is Determined by a Balance Between SNAIL and ID Factors. [Abstract]2021 Feb 12:9:616610. PMID: 33644053 -
Cancers (Basel)
Chemotherapy Enrichment of ID Family Expression Is Associated with IL-6 Signaling in Ovarian Cancer. [Abstract]2026 Apr 8;18(8):1186. PMID: 42073515 -
Mol Oncol
2025 Mar 21. PMID: 40116596 -
San Diego State University
-
-
-
Solvant et solubilité
DMSO : 100 mg/mL (231.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 100 mg/mL (231.74 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.82 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (287 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Ethanol | 1 mM | 2.3174 mL | 11.5869 mL | 23.1739 mL | 57.9347 mL |
| 5 mM | 0.4635 mL | 2.3174 mL | 4.6348 mL | 11.5869 mL | |
| 10 mM | 0.2317 mL | 1.1587 mL | 2.3174 mL | 5.7935 mL | |
| 15 mM | 0.1545 mL | 0.7725 mL | 1.5449 mL | 3.8623 mL | |
| 20 mM | 0.1159 mL | 0.5793 mL | 1.1587 mL | 2.8967 mL | |
| 25 mM | 0.0927 mL | 0.4635 mL | 0.9270 mL | 2.3174 mL | |
| 30 mM | 0.0772 mL | 0.3862 mL | 0.7725 mL | 1.9312 mL | |
| 40 mM | 0.0579 mL | 0.2897 mL | 0.5793 mL | 1.4484 mL | |
| 50 mM | 0.0463 mL | 0.2317 mL | 0.4635 mL | 1.1587 mL | |
| 60 mM | 0.0386 mL | 0.1931 mL | 0.3862 mL | 0.9656 mL | |
| 80 mM | 0.0290 mL | 0.1448 mL | 0.2897 mL | 0.7242 mL | |
| 100 mM | 0.0232 mL | 0.1159 mL | 0.2317 mL | 0.5793 mL |
AGX51 Related Classifications
HY-129241 Related Classifications
Powered by Bioz